Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRIM33 | Q9UPN9 | 15/20 | 0.61 |
| ▸ | BAZ2B | Q9UIF8 | 5/20 | 0.61 |
| ▸ | BAZ2A | Q9UIF9 | 4/20 | 0.61 |
| ▸ | BRD9 | Q9H8M2 | 3/20 | 0.61 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.61 |
| ▸ | TAF1L | Q8IZX4 | 1/20 | 0.61 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.59 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29352262 | 0.76 | BAZ2B (1.00) | TRIM33BAZ2BBAZ2ABRD9TRIM24 | |
| SCHEMBL22339997 | 0.76 | BAZ2B (1.00) | TRIM33BAZ2BBAZ2ABRD9TRIM24 | |
| SCHEMBL30427435 | 0.75 | BRD9 (1.00) | TRIM33BAZ2BBAZ2ABRD9TRIM24 | |
| SCHEMBL9150850 | 0.65 | ALDH1A1 (0.53) | — | |
| SCHEMBL27028357 | 0.64 | KMT2A (0.47) | BAZ2BBRD9 | |
| SCHEMBL8008640 | 0.64 | RXRA (0.44) | — | |
| SCHEMBL24510741 | 0.63 | BAZ2B (0.57) | TRIM33BAZ2BBAZ2ABRD9TRIM24 | |
| SCHEMBL278552 | 0.63 | LMNA (0.42) | — | |
| SCHEMBL25946876 | 0.63 | PTGS1 (0.43) | — | |
| SCHEMBL24510740 | 0.62 | FNTA (0.60) | BAZ2BBAZ2ABRD9SMARCA2SMARCA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067641-A1 | INHIBITORS OF TRIM33 AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-02-29 | — | — | US | disclosed |
| US-20240067641-A1 | INHIBITORS OF TRIM33 AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-02-29 | — | — | US | disclosed |
| US-11731967-B2 | Inhibitors of TRIM33 and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-11731967-B2 | Inhibitors of TRIM33 and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-20200255422-A1 | INHIBITORS OF TRIM33 AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11731967-B2 | Inhibitors of TRIM33 and methods of use | TRIM33, TRIM28, TRIM4 | TRIM33 1/4885BAZ2B 119/4885BAZ2A 130/4885 |
| US-20200255422-A1 | INHIBITORS OF TRIM33 AND METHODS OF USE | TRIM33, TRIM28, TRIM4 | TRIM33 1/4885BAZ2B 119/4885BAZ2A 130/4885 |
| US-20240067641-A1 | INHIBITORS OF TRIM33 AND METHODS OF USE | TRIM33, TRIM28, TRIM4 | TRIM33 1/4885BAZ2B 119/4885BAZ2A 130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.